Join us at Europe’s Leading Drug Safety & Pharmacovigilance Event—the World Drug Safety Congress Europe 2024! This two-day event will bring together over 1,500 key thought leaders to explore key challenges in pharmacovigilance.

From exploring the use of big data and AI in pharmacovigilance, examining benefit-risk management strategies and patient centric approaches, drug safety is at the forefront of innovative technologies that will have an impact on the lives of patients.

Content tracks include:

We will also be exhibiting at booth #98 throughout the event. Make sure to visit us to learn more about our services and how we can help you navigate the evolving landscape of pharmacovigilance/drug safety and more!

Be part of this crucial event and explore the latest trends in drug safety that will improve patient lives globally. We look forward to welcoming you to Amsterdam in October 2024!For more details, check agenda at https://www.terrapinn.com/conference/world-drug-safety-congress-europe/agenda.stm

Joint Workshop of AKRA TEAM GmbH &
Dr. Ebeling & Assoc. GmbH

register now

Drug-Device-Combinations (DDCs) represent a heterogenous group of products, which are a combination of medical devices on one hand and pharmaceutical products on the other. This product group has evolved significantly over the past years as it bears a high potential of clinical benefits for treatment of various types of diseases.

The product spectrum ranges from simple prefilled syringes (filled with a drug component), auto injection devices to complex delivery on demand devices which are implanted (e.g. insulin pumps). Other devices represent a combination of a traditional medical device (e.g. a stent) coated with a pharmaceutical to improve the clinical outcome of the treatment (e.g. drug eluting stent). Depending on the principal mode of action, either the medical device regulation (Regulation 2017/745) or medicinal products directive (Directive 2001/83/EC) is the primary applicable legislation.

This has significant impact on the legislative processes to be applied. In addition, article 117 of the EU MDR specifically bears new obligations for pharmaceutical manufacturers.

This one-day workshop provided by specialists of AKRA TEAM GmbH and Dr. Ebeling & Assoc. GmbH will provide a structured step-by-step approach, how the different legislations are to be considered and applied for different types of DDCs.

Overview of covered topics

Purpose of the training

The participants shall be enabled to:

Who should attend

Basic knowledge required

Presenting experts

Our trainers have long-time experience working with one of the biggest notified bodies and in clinical research and regulatory consulting as well as pharma.